Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Call Transcript
Matt Scalo: Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
Stay updated with breaking news from Genetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Matt Scalo: Good afternoon and welcome to Myriad Genetics Third Quarter 2023 Earnings Call. During the call, we will review the financial results we released today.
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today...
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from $17.00 to $14.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of 21.30% […]
/PRNewswire/ -- Allied Market Research published a report, titled, "Genetic Testing Market by Type (Predictive & Pre-Symptomatic Testing, Carrier Testing,...